BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2026-11
189 industry Phase 2/3 trial readout(s) and 20 FDA decision event(s). Past days: any status; from today on: active trials only.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P2 | BeiGene | NCT03736889 Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors | MSI-H/dMMR Solid Tumors | recruiting | 200 |
| 2026-11 est. | P1/P2 | Aptose Biosciences Inc. | NCT03850574 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute | Leukemia, Myeloid, Acute; Refractory AML; Relapsed Adult AML; Myelodysplastic Syndrome With Excess B | recruiting | 240 |
| 2026-11 est. | P2 | BioNTech SE BNTX | NCT04486378 A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage I | Colorectal Cancer Stage II; Colorectal Cancer Stage III | active not recruiting | 327 |
| 2026-11 est. | P3 | Octapharma | NCT04640142 Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficie | Primary Immune Deficiency | active not recruiting | 50 |
| 2026-11 est. | P2 | AbbVie ABBV | NCT04895436 Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic | Chronic Lymphocytic Leukemia (CLL) | recruiting | 75 |
| 2026-11 est. | P1/P2 | BeOne Medicines ONC | NCT04973605 A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, an | Relapsed/Refractory Multiple Myeloma | recruiting | 246 |
| 2026-11 est. | P3 | Camurus AB | NCT05050942 A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET | Gastro-enteropancreatic Neuroendocrine Tumor | active not recruiting | 332 |
| 2026-11 est. | P1/P2 | Talaris Therapeutics Inc. | NCT05098145 A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis | Diffuse Cutaneous Systemic Sclerosis | withdrawn | |
| 2026-11 est. | P3 | Immunic AG IMUX | NCT05134441 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | Multiple Sclerosis | active not recruiting | 1121 |
| 2026-11 est. | P3 | Immunic AG IMUX | NCT05201638 Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | active not recruiting | 1100 |
| 2026-11 est. | P3 | NewAmsterdam Pharma NAMS | NCT05202509 Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | Atherosclerotic Cardiovascular Disease | active not recruiting | 9541 |
| 2026-11 est. | P1/P2 | Bexion Pharmaceuticals, Inc. | NCT05322590 BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma | Metastatic Colorectal Carcinoma; Neuropathy | active not recruiting | 195 |
| 2026-11 est. | P3 | Oncternal Therapeutics, Inc | NCT05431179 A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma | Lymphoma, Mantle-Cell; Lymphoma; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferat | withdrawn | |
| 2026-11 est. | P2 | AbbVie ABBV | NCT05456685 Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Canc | High Grade Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer | active not recruiting | 125 |
| 2026-11 est. | P2 | Pharmazz, Inc. | NCT05514340 Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy | Hypoxic-Ischemic Encephalopathy; Neonatal Asphyxia; Neonatal Encephalopathy | recruiting | 40 |
| 2026-11 est. | P1/P2 | Anbogen Therapeutics, Inc. | NCT05532696 Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients | Advanced Solid Tumor; Non Small Cell Lung Cancer; HER2 Mutations | recruiting | 61 |
| 2026-11 est. | P2 | IGC Pharma, LLC IGC | NCT05543681 Clinical Trial on Agitation in Alzheimer's Dementia | Alzheimer Disease; Agitation,Psychomotor; Care Giving Burden; NPS; Aggression | active not recruiting | 164 |
| 2026-11 est. | P1/P2 | Tyra Biosciences, Inc TYRA | NCT05544552 Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Solid Tumor; Urothelial Carc | active not recruiting | 310 |
| 2026-11 est. | P2 | Stemline Therapeutics, Inc. | NCT05596409 ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study | Metastatic Breast Cancer | active not recruiting | 61 |
| 2026-11 est. | P2 | Atossa Therapeutics, Inc. ATOS | NCT05607004 (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer | Breast Neoplasms; Invasive Breast Cancer; Estrogen-receptor-positive Breast Cancer; HER2-negative Br | active not recruiting | 87 |
| 2026-11 est. | P2 | Beckley Psytech Limited | NCT05660642 An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression | Treatment Resistant Depression | recruiting | 72 |
| 2026-11 est. | P2 | AbbVie ABBV | NCT05822752 Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab | Hepatocellular Carcinoma | active not recruiting | 130 |
| 2026-11 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06015048 A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors. | HER2-expressing Advanced Solid Tumors | recruiting | 364 |
| 2026-11 est. | P2 | TBF Genie Tissulaire | NCT06038331 Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of STT Osteoarthritis | Osteoarthritis Hand | active not recruiting | 14 |
| 2026-11 est. | P2 | MediLink Therapeutics (Suzhou) Co., Ltd. | NCT06107686 A Study of YL202 in Selected Patients With Advanced Solid Tumors | NSCLC; Breast Cancer; HNSCC; Locally Advanced or Metastatic Solid Tumors | recruiting | 200 |
| 2026-11 est. | P3 | CG Oncology, Inc. CGON | NCT06111235 A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | Non Muscle Invasive Bladder Cancer; Urologic Cancer; Bladder Cancer; Urothelial Carcinoma | active not recruiting | 367 |
| 2026-11 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06118333 A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) | Nasopharyngeal Carcinoma | active not recruiting | 386 |
| 2026-11 est. | P2 | ReCode Therapeutics | NCT06237335 A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF | Cystic Fibrosis | active not recruiting | 128 |
| 2026-11 est. | P3 | medac GmbH | NCT06239311 Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis. | Moderate to Severe Atopic Dermatitis | recruiting | 277 |
| 2026-11 est. | P2 | argenx ARGX | NCT06284954 A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis | Dermatomyositis; Myositis | active not recruiting | 3 |
| 2026-11 est. | P3 | Akeso | NCT06341335 A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric and Gastroesophageal Junction Adenocarcinoma | recruiting | 506 |
| 2026-11 est. | P3 | AbbVie ABBV | NCT06389136 A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | Atopic Dermatitis | active not recruiting | 184 |
| 2026-11 est. | P2 | Apogee Therapeutics, Inc. APOG | NCT06395948 A Study Evaluating APG777 in Atopic Dermatitis | Atopic Dermatitis | active not recruiting | 470 |
| 2026-11 est. | P3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT06448312 A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | active not recruiting | 406 |
| 2026-11 est. | P2 | NewAmsterdam Pharma NAMS | NCT06496243 Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels | Dyslipidemias | recruiting | 69 |
| 2026-11 est. | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06529432 A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery | Local Analgesia Via Nerve Block | recruiting | 96 |
| 2026-11 est. | P2 | BeOne Medicines ONC | NCT06637501 A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | active not recruiting | 94 |
| 2026-11 est. | P3 | Eli Lilly and Company LLY | NCT06662383 A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | Obesity | active not recruiting | 800 |
| 2026-11 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06668961 A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cel | Head and Neck Squamous Cell Carcinoma | active not recruiting | 48 |
| 2026-11 est. | P2 | Calluna Pharma AS | NCT06736990 A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | active not recruiting | 150 |
| 2026-11 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06737731 A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors | Malignant Solid Tumors | recruiting | 300 |
| 2026-11 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | NCT06767813 Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms | Pancreatic Neoplasms | recruiting | 80 |
| 2026-11 est. | P2 | Kiora Pharmaceuticals, Inc. KPRX | NCT06825702 Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema | Macular Edema | recruiting | 28 |
| 2026-11 est. | P1/P2 | Aldena Therapeutics | NCT06826196 A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata | Alopecia Areata (AA) | active not recruiting | 9 |
| 2026-11 est. | P2 | ImmunityBio, Inc. IBRX | NCT06829823 Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer | Non-muscle Invasive Bladder Cancer (NMIBC) | not yet recruiting | 20 |
| 2026-11 est. | P2 | KeyBioscience AG | NCT06833749 Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis | Osteoarthritis in the Knee; Obesity | recruiting | 600 |
| 2026-11 est. | P2 | Alkermes, Inc. ALKS | NCT06843590 A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia | Idiopathic Hypersomnia | active not recruiting | 126 |
| 2026-11 est. | P2 | AbbVie ABBV | NCT06846320 Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anx | Generalized Anxiety Disorder (GAD) | recruiting | 315 |
| 2026-11 est. | P3 | EirGenix, Inc. | NCT06884254 Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negat | Early Breast Cancer | withdrawn | |
| 2026-11 est. | P2 | Pacira Pharmaceuticals, Inc PCRX | NCT06884865 A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee | Osteoarthritis (OA) of the Knee | recruiting | 135 |
| 2026-11 est. | P3 | Eli Lilly and Company LLY | NCT06914895 A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | Type 1 Diabetes; Obesity; Overweight | active not recruiting | 905 |
| 2026-11 est. | P3 | Agitated Solutions, Inc. | NCT06938347 Comparing the Safety and Efficacy of ASI-02 to Agitated Saline for Suspected Right-to-left Shunt | Right-To-Left Shunt | recruiting | 300 |
| 2026-11 est. | P3 | Eli Lilly and Company LLY | NCT06962280 A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | Type 1 Diabetes; Obesity; Overweight | active not recruiting | 465 |
| 2026-11 est. | P3 | DBV Technologies DBVT | NCT07003919 Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | Allergy; Peanut Allergy | active not recruiting | 480 |
| 2026-11 est. | P3 | Wooshin Labottach Co., Ltd. | NCT07029516 Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis | Nail Psoriasis; Nail Damage; Mycosis | recruiting | 72 |
| 2026-11 est. | P2 | BRIM Biotechnology Inc. | NCT07078955 A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease | Dry Eye Disease (DED); Keratoconjunctivitis Sicca | not yet recruiting | 99 |
| 2026-11 est. | P1/P2 | TYK Medicines, Inc | NCT07104643 Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC) | mCRPC | not yet recruiting | 48 |
| 2026-11 est. | P2 | Arthrosi Therapeutics | NCT07116746 Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients | Gout; Gouty Arthritis; Hyperuricemia; Gout Chronic; Refractory Gout; Uncontrolled Gout; Tophaceous G | active not recruiting | 15 |
| 2026-11 est. | P3 | Nanjing Chia-tai Tianqing Pharmaceutical | NCT07177859 A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients | Paroxysmal Nocturnal Hemoglobinuria | not yet recruiting | 78 |
| 2026-11 est. | P2 | SciNeuro | NCT07199777 A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients | Diabetic Macular Edema; DME | not yet recruiting | 60 |
| 2026-11 est. | P2 | Eli Lilly and Company LLY | NCT07215312 A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin | Diabetes Mellitus, Type 2 | active not recruiting | 100 |
| 2026-11 est. | P3 | Lynk Pharmaceuticals Co., Ltd | NCT07237568 A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis | Ankylosing Spondylitis | recruiting | 352 |
| 2026-11 est. | P3 | Verrica Pharmaceuticals Inc. VRCA | NCT07246590 Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) | Common Warts; Common Warts (Verruca Vulgaris); Human Papilloma Virus (HPV); Warts | active not recruiting | 302 |
| 2026-11 est. | P3 | Waterstone Pharmaceutical (Wuhan) Co., LTD. | NCT07251309 A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia | Hyperkalemia | recruiting | 420 |
| 2026-11 est. | P2 | Bright Minds Biosciences Pty Ltd DRUG | NCT07266324 A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome. | Prader-Willi Syndrome | not yet recruiting | 16 |
| 2026-11 est. | P2/P3 | Nuance Hearing | NCT07282028 A Prospective, Open-label, Pivotal Study to Assess Spectacle Hearing Aid Safety and Efficacy | Hearing Loss Mixed | recruiting | 89 |
| 2026-11 est. | P2 | Avistone Biotechnology Co., Ltd. | NCT07336732 Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations | Non-Small-Cell Lung Cancer | recruiting | 40 |
| 2026-11 est. | P2 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | NCT07398859 Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis | Seasonal Allergic Rhinitis | recruiting | 300 |
| 2026-11 est. | P2 | Shandong Suncadia Medicine Co., Ltd. | NCT07470983 A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism | Primary Aldosteronism | active not recruiting | 61 |
| 2026-11 est. | P2 | Traws Pharma, Inc. TRAW | NCT07503405 Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model | Influenza | not yet recruiting | 165 |
| 2026-11 est. | P3 | Sinovac Biotech Co., Ltd SVA | NCT07505888 Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years | Epidemic Meningitis; Meningococcal Vaccines | active not recruiting | 660 |
| 2026-11 est. | P2 | Eli Lilly and Company LLY | NCT07511816 A Study of LY4515100 in Participants With Pain Following Third Molar Removal | Acute Pain; Molar; Molar, Third; Surgery, Oral | recruiting | 212 |
| 2026-11 est. | P2 | NeuShen Therapeutics | NCT07521683 A Phase II Clinical Study to Evaluate the Efficacy and Safety of NS-136 in the Treatment of Schizophrenia | Schizophrenia(Acute) | enrolling by invitation | 150 |
| 2026-11 est. | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT07551739 A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Orthopedic Surgery | Pain After Surgery | not yet recruiting | 200 |
| 2026-11 est. | P3 | Alcon Research ALC | NCT07578363 An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults | Ocular Hyperemia | recruiting | 178 |
| 2026-11 est. | P3 | Colgate Palmolive CL | NCT07605338 To Assess the Efficacy of Two Brushing Regimens: in the Reduction of Established Dental Plaque and Gingivitis. | Plaque, Dental; Gingivitis | active not recruiting | 85 |
| 2026-11-01 est. | P2 | ML Bio Solutions, Inc. | NCT04800874 Study of BBP-418 in Patients With LGMD2I | LGMD2I | active not recruiting | 14 |
| 2026-11-01 est. | P2/P3 | Mirror Biologics, Inc. | NCT05033522 Immunotherapy for Advanced Liver Cancer | Hepatocellular Carcinoma | suspended | 150 |
| 2026-11-01 est. | P3 | Epygenix | NCT05066217 An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome | Lennox Gastaut Syndrome | recruiting | 260 |
| 2026-11-01 est. | P1/P2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | NCT05584800 Study of ZGGS18 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | recruiting | 222 |
| 2026-11-01 est. | P3 | Scholar Rock, Inc. SRRK | NCT05626855 Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab | Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2; SMA; Neurom | active not recruiting | 238 |
| 2026-11-01 est. | P3 | Bristol-Myers Squibb BMY | NCT06951698 A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder | Bipolar-I Disorder With Mania or Mania With Mixed Features | recruiting | 274 |
| 2026-11-02 | P2/P3 | Hoffmann-La Roche | NCT05115110 A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy | Spinal Muscular Atrophy (SMA) | completed | 97 |
| 2026-11-02 est. | P2 | GlaxoSmithKline | NCT05723562 A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer | Neoplasms, Rectal | active not recruiting | 154 |
| 2026-11-02 | P3 | AstraZeneca AZN | NCT06015737 A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus | Cutaneous Lupus Erythematosus | active not recruiting | 339 |
| 2026-11-02 est. | P2 | Regeneron Pharmaceuticals REGN | NCT06190951 A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma | Melanoma | active not recruiting | 151 |
| 2026-11-02 est. | P3 | Bristol-Myers Squibb BMY | NCT06951711 A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2) | Bipolar Disorder Type I With Mania or Mania With Mixed Features | recruiting | 274 |
| 2026-11-02 est. | P2 | Keymed Biosciences Co.Ltd | NCT07166211 Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU) | Chronic Spontaneous Urticaria (CSU) | recruiting | 48 |
| 2026-11-03 | P1/P2 | Solid Biosciences Inc. SLDB | NCT03368742 Microdystrophin Gene Transfer Study in Adolescents and Children With DMD | Duchenne Muscular Dystrophy | completed | 12 |
| 2026-11-03 est. | P3 | Novartis Pharmaceuticals NVS | NCT05677451 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response | Chronic Spontaneous Urticaria | active not recruiting | 100 |
| 2026-11-03 | P2/P3 | Gilead Sciences GILD | NCT06544733 Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Su | HIV-1-Infection | terminated | 80 |
| 2026-11-03 | P2 | Rhythm Pharmaceuticals, Inc. RYTM | NCT06772597 A Study of Setmelanotide in Patients With Prader-Willi Syndrome | Prader-Willi Syndrome; Obesity; Hyperphagia | active not recruiting | 18 |
| 2026-11-03 | P3 | Sandoz | NCT06847724 Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis | Relapsing Multiple Sclerosis | active not recruiting | 183 |
| 2026-11-04 | P3 | THPharm Corp. | NCT06647745 A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP | Type 2 Diabetes; Hypertension | active not recruiting | 222 |
| 2026-11-04 est. | P3 | CMG Pharmaceutical Co. Ltd | NCT06772168 Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia | Dyslipidemia; Type 2 Diabetes | recruiting | 240 |
| 2026-11-04 | P3 | Colgate Palmolive CL | NCT07917507 Efficacy of Two Brushing Regimens in the Reduction of Established Dental Plaque and Gingivitis | Plaque; Gingivitis | completed | 84 |
| 2026-11-05 est. | P2 | Incyte Corporation INCY | NCT04509700 Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) | B-Cell Malignancies | active not recruiting | 112 |
| 2026-11-05 est. | P1/P2 | AstraZeneca AZN | NCT07336446 A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs | Prostate Cancer | active not recruiting | 6 |
| 2026-11-06 est. | P2 | Novartis Pharmaceuticals NVS | NCT06004661 Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | active not recruiting | 23 |
| 2026-11-06 est. | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT07150988 A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis | Psoriasis | not yet recruiting | 150 |
| 2026-11-09 est. | P3 | LEAF4Life, Inc. | NCT06640777 Efficacy and Safety of LEAF-4L6715 for Acute Respiratory Distress Syndrome | Acute Respiratory Distress Syndrome | not yet recruiting | 310 |
| 2026-11-10 est. | P1/P2 | HELP Therapeutics Co., Ltd. | NCT06340048 Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure | Heart Failure | active not recruiting | 36 |
| 2026-11-10 est. | P3 | LaNova Medicines Zhejiang Co., Ltd. | NCT06351020 LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. | Locally Advanced or Metastatic GC and GCJ Adenocarcinoma | active not recruiting | 387 |
| 2026-11-10 est. | P3 | Gan & Lee Pharmaceuticals. | NCT07165223 A Phase IIIb Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin | Diabetes | recruiting | 300 |
| 2026-11-11 est. | P2 | Precigen, Inc PGEN | NCT06157151 PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer | Cervical Cancer; HPV-Related Carcinoma; HPV-Related Malignancy; Recurrent Cervical Carcinoma; Metast | recruiting | 24 |
| 2026-11-11 est. | P3 | Tasly Pharmaceutical Group Co., Ltd | NCT06753890 Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern) | Diarrhea-predominant Irritable Boewl Syndrome | not yet recruiting | 520 |
| 2026-11-12 est. | P2 | Pfizer PFE | NCT05995964 A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis | Atopic Dermatitis | active not recruiting | 507 |
| 2026-11-12 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT06671548 Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | Heavy Menstrual Bleeding; Uterine Fibroids | recruiting | 120 |
| 2026-11-12 est. | P2 | Longbio Pharma (Suzhou) Co., Ltd. | NCT07603713 Efficacy and Safety of LP-005 Injection in Patients With Moderate-to-Severe Periodontitis | Periodontitis | not yet recruiting | 100 |
| 2026-11-13 est. | P1/P2 | Regeneron Pharmaceuticals REGN | NCT04626635 A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers | Advanced Solid Tumors | active not recruiting | 548 |
| 2026-11-13 est. | P3 | Hoffmann-La Roche | NCT05646862 A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negati | Breast Cancer | recruiting | 420 |
| 2026-11-13 est. | P1/P2 | Shanghai Runshi Pharmaceutical Technology Co., Ltd | NCT06682611 Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors. | Unresectable Locally Advanced or Metastatic Solid Tumors | not yet recruiting | 380 |
| 2026-11-13 est. | P2 | Regeneron Pharmaceuticals REGN | NCT07431086 Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US | Overweight or Obesity | active not recruiting | 120 |
| 2026-11-15 est. | P2 | PolyActiva Pty Ltd | NCT06964191 Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension | Glaucoma, Open-Angle; Ocular Hypertension | active not recruiting | 75 |
| 2026-11-15 est. | P3 | Achieve Life Sciences QUIT | NCT07392125 Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes | Vaping Cessation | not yet recruiting | 800 |
| 2026-11-15 est. | P2 | ImmunityBio, Inc. IBRX | NCT07492888 Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) | Acute Respiratory Distress Syndrome; Severe Community-Acquired Pneum; Sepsis; Lymphopenia / Immunopa | withdrawn | |
| 2026-11-17 est. | P2 | AstraZeneca AZN | NCT06219941 AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer; Pancreatic Ductal Adenocarci | recruiting | 226 |
| 2026-11-17 est. | P2 | Novartis Pharmaceuticals NVS | NCT06894511 An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC | Metastatic Castration Resistant Prostate Cancer (mCRPC) | active not recruiting | 7 |
| 2026-11-18 est. | P2/P3 | Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair | NCT01064466 Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms | Small Cell Lung Cancer | active not recruiting | 600 |
| 2026-11-18 est. | P2/P3 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | NCT03348670 Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms | Prostate Cancer | active not recruiting | 600 |
| 2026-11-18 est. | P3 | Bristol-Myers Squibb BMY | NCT05946941 A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome | Sjögren's Syndrome | active not recruiting | 774 |
| 2026-11-18 est. | P2/P3 | Medicine Invention Design, Inc | NCT05987956 Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms | ALK-Positive Non-Small Cell Lung Cancer (NSCLC) | active not recruiting | 600 |
| 2026-11-18 est. | P2 | Hoffmann-La Roche | NCT06450639 A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) | Duchenne Muscular Dystrophy | active not recruiting | 30 |
| 2026-11-18 est. | P2 | ToLymph Inc. | NCT06693336 An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung Cancer (NSCLC) | recruiting | 42 |
| 2026-11-19 est. | P2 | Hoffmann-La Roche | NCT06402838 A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD) | Alzheimer's Disease | active not recruiting | 256 |
| 2026-11-19 est. | P2 | Janssen Research & Development, LLC | NCT07230860 A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis | Dermatitis, Atopic | active not recruiting | 189 |
| 2026-11-20 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT04634877 Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer | Endometrial Neoplasms | active not recruiting | 990 |
| 2026-11-20 est. | P2 | Incyte Corporation INCY | NCT05851443 A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma | Moderate to Severe Asthma | active not recruiting | 247 |
| 2026-11-20 est. | P2 | Skye Bioscience, Inc. SKYE | NCT06577090 Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo | Obesity | active not recruiting | 136 |
| 2026-11-21 est. | P3 | Changchun GeneScience Pharmaceutical Co., Ltd. | NCT07124221 A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets | Hyperprolactinemia | recruiting | 382 |
| 2026-11-22 est. | P1/P2 | Resverlogix Corp | NCT03160430 A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis | Kidney Failure, Chronic | not yet recruiting | 44 |
| 2026-11-22 est. | P2 | Shanghai Henlius Biotech | NCT06839066 A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy | Nasopharyngeal Carcinoma (NPC) | recruiting | 70 |
| 2026-11-22 est. | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT07533786 A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Abdominal Surgery | Pain After Surgery | recruiting | 200 |
| 2026-11-23 est. | P2 | GlaxoSmithKline | NCT06567782 A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient | Neoplasms, Colon | recruiting | 120 |
| 2026-11-23 est. | P3 | GlaxoSmithKline | NCT06693895 A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age | Chickenpox | recruiting | 750 |
| 2026-11-23 est. | P3 | GlaxoSmithKline | NCT07596199 A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women | Diphtheria-Tetanus-acellular Pertussis Vaccines | active not recruiting | 102 |
| 2026-11-24 est. | P3 | EMD Serono Research & Development Institute, Inc. | NCT03815643 Avelumab Program Rollover Study | Solid Tumors | active not recruiting | 205 |
| 2026-11-24 est. | P1/P2 | AstraZeneca AZN | NCT06267729 Study of AZD0754 in Participants With Metastatic Prostate Cancer | Metastatic Prostate Cancer | recruiting | 60 |
| 2026-11-24 est. | P3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | NCT06585787 A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | Alzheimer Disease | recruiting | 406 |
| 2026-11-24 est. | P2 | Tectonic Therapeutic TECX | NCT06616974 A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) | Pulmonary Hypertension; Heart Failure With Preserved Ejection Fraction | active not recruiting | 191 |
| 2026-11-24 est. | P3 | HTA Co., Ltd. | NCT07057622 A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs | NETS Ga68 Lu177 | recruiting | 184 |
| 2026-11-24 est. | P1/P2 | CanSino Biologics Inc. | NCT07600983 Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) | Streptococcus Pneumoniae Infection | recruiting | 854 |
| 2026-11-25 est. | P3 | Beijing InnoCare Pharma Tech Co., Ltd. | NCT06775860 ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | recruiting | 552 |
| 2026-11-25 est. | P3 | Sanofi SNY | NCT07216079 Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan | Immune Thrombocytopenia | active not recruiting | 3 |
| 2026-11-26 est. | P3 | Tesaro, Inc. | NCT03981796 A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endome | Neoplasms | active not recruiting | 785 |
| 2026-11-26 est. | P3 | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | NCT07122401 Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism | Secondary Hyperparathyroidism, Chronic Kidney Disease | recruiting | 424 |
| 2026-11-28 est. | P3 | Haisco Pharmaceutical Group Co., Ltd. | NCT06660992 A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis | Non-cystic Fibrosis Bronchiectasis | recruiting | 669 |
| 2026-11-28 est. | P2 | TrueBinding, Inc. | NCT06773962 A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease | Parkinson's Disease (PD) | active not recruiting | 62 |
| 2026-11-28 est. | P3 | Sanofi SNY | NCT07103148 A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population | Yellow Fever Immunization | active not recruiting | 2440 |
| 2026-11-29 est. | P3 | Pfizer PFE | NCT06641466 A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | Menstrual Migraine | recruiting | 723 |
| 2026-11-30 est. | P1/P2 | Neonc Technologies, Inc. NTHI | NCT02704858 Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | Glioblastoma Multiforme | active not recruiting | 49 |
| 2026-11-30 est. | P3 | Hoffmann-La Roche | NCT03148418 A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) | Cancer | active not recruiting | 382 |
| 2026-11-30 est. | P1/P2 | BeyondBio Inc. | NCT03579836 Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer | Locally Advanced or Metastatic Pancreatic Cancer | recruiting | 75 |
| 2026-11-30 est. | P1/P2 | Celgene | NCT03989414 A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in | Multiple Myeloma | active not recruiting | 424 |
| 2026-11-30 est. | P2 | Genentech, Inc. | NCT04302025 A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) | Non-small Cell Lung Cancer | active not recruiting | 99 |
| 2026-11-30 est. | P1/P2 | BeyondBio Inc. | NCT05093907 A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | recruiting | 27 |
| 2026-11-30 est. | P1/P2 | Amgen AMGN | NCT05094336 A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | Advanced MTAP-null Solid Tumors | active not recruiting | 329 |
| 2026-11-30 est. | P1/P2 | ModernaTX, Inc. | NCT05095727 A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a) | Glycogen Storage Disease | active not recruiting | 15 |
| 2026-11-30 est. | P2 | NeuroPace NPCE | NCT05339126 RNS System LGS Feasibility Study | Epilepsy; Lennox Gastaut Syndrome; Lennox-Gastaut Syndrome, Intractable; Seizures; Seizures, General | active not recruiting | 24 |
| 2026-11-30 est. | P3 | Pharming Technologies B.V. PHAR | NCT05438407 Pediatric Patients Aged 4 to 11 Years With APDS | APDS | active not recruiting | 15 |
| 2026-11-30 est. | P3 | AUG Therapeutics | NCT05462587 A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type II | Leukocyte Adhesion Deficiency | recruiting | 4 |
| 2026-11-30 est. | P1/P2 | OncoC4, Inc. | NCT05682443 ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC | Metastatic Castration-resistant Prostate Cancer | active not recruiting | 148 |
| 2026-11-30 est. | P1/P2 | Xentria, Inc. | NCT05890729 Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations | Pulmonary Sarcoidosis | active not recruiting | 32 |
| 2026-11-30 est. | P2/P3 | CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd. | NCT05924776 Plasmodium Immunotherapy for Advanced Ovarian Cancer | Advanced Ovarian Cancer | not yet recruiting | 30 |
| 2026-11-30 est. | P1/P2 | UniQure Biopharma B.V. QURE | NCT06063850 AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy | Mesial Temporal Lobe Epilepsy | recruiting | 12 |
| 2026-11-30 est. | P2/P3 | Cytopeutics Sdn. Bhd. | NCT06129175 UCMSCs as Treatment for Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX) | Acute Ischemic Stroke | recruiting | 80 |
| 2026-11-30 est. | P1/P2 | OriCell Therapeutics Co., Ltd. | NCT06182696 OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM | Relapsed and/or Refractory Multiple Myeloma | recruiting | 83 |
| 2026-11-30 est. | P1/P2 | Bio-Thera Solutions | NCT06341114 A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Pa | Advanced Solid Tumors | active not recruiting | 112 |
| 2026-11-30 est. | P2 | Aura Biosciences AURA | NCT06643884 Suprachoroidal Administration in Subjects With Metastases to the Choroid | Eye Cancer; Primary Cancer | recruiting | 24 |
| 2026-11-30 est. | P1/P2 | Nuwacell Biotechnologies Co., Ltd. | NCT06741098 A Study of NCR100 Injection for the Treatment of Knee Osteoarthritis( KOA) | Knee Osteoarthritis | not yet recruiting | 162 |
| 2026-11-30 est. | P2 | Mundipharma Research Limited | NCT06794554 Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options | Chronic Pulmonary Aspergillosis | active not recruiting | 60 |
| 2026-11-30 est. | P2 | Takeda TAK | NCT06812078 A Study of TAK-360 in Adults With Idiopathic Hypersomnia | Idiopathic Hypersomnia | recruiting | 96 |
| 2026-11-30 est. | P3 | Gritgen Therapeutics Co., Ltd. | NCT06833983 To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A | Hemophilia A | recruiting | 50 |
| 2026-11-30 est. | P1/P2 | Immunocore Ltd IMCR | NCT06840119 Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers | Cancer; HLA-A*02:01-positive | recruiting | 600 |
| 2026-11-30 est. | P2 | Takeda TAK | NCT06952699 A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) | Narcolepsy Type 2 | recruiting | 88 |
| 2026-11-30 est. | P3 | InventisBio Co., Ltd | NCT06954961 A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer | Breast Cancer | recruiting | 640 |
| 2026-11-30 est. | P3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT06968585 A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab | HER2-positive Breast Cancer | active not recruiting | 365 |
| 2026-11-30 est. | P2 | Akeso | NCT06984718 A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC | HCC; Hepatocellular Carcinoma | not yet recruiting | 120 |
| 2026-11-30 est. | P2 | AstraZeneca AZN | NCT07081633 Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma | Hepatocellular Carcinoma | active not recruiting | 114 |
| 2026-11-30 est. | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07122687 IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung | Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer | recruiting | 170 |
| 2026-11-30 est. | P2 | Bavarian Nordic | NCT07199569 Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells | Monkeypox (Mpox) | active not recruiting | 970 |
| 2026-11-30 est. | P3 | Saol Therapeutics Inc | NCT07226258 Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain | Osteoarthritis Knee Pain | active not recruiting | 150 |
| 2026-11-30 est. | P2 | CSPC Megalith Biopharmaceutical Co.,Ltd. | NCT07256509 A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous No | Non-Small Cell Lung Cancer | not yet recruiting | 120 |
| 2026-11-30 est. | P1/P2 | Shanghai JMT-Bio Inc. | NCT07280832 Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors | Unresectable Locally Advanced or Metastatic Melanoma; Unresectable Locally Advanced or Metastatic Ur | recruiting | 500 |
| 2026-11-30 est. | P2 | Ranok Therapeutics (Hangzhou) Co., Ltd. | NCT07303465 To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. | KRAS G12D Mutations; Pancreatic Ductal Adenocarcinoma (PDAC) | recruiting | 60 |
| 2026-11-30 est. | P2 | Mylan Pharmaceuticals Inc | NCT07365904 Investigating Ovulation Inhibition for Use as a Contraceptive | Contraception | recruiting | 60 |
| 2026-11-30 est. | P3 | Taisho Pharmaceutical Co., Ltd. | NCT07548840 A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis | Hyperphosphatemia Patients on Hemodialysis | active not recruiting | 34 |
| 2026-11-30 est. | P2 | BioAge Labs, Inc. BIOA | NCT07656727 A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors | Obesity and Cardiovascular Risk | active not recruiting | 160 |
| 2026-11-30 est. | P3 | Zhejiang Wenda Pharma Technology LTD. | NCT07672561 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to | Moderate to Severe Plaque Psoriasis | recruiting | 375 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.